Avenue TherapeuticsATXI -8.35%33 PB Ratio is 0.77 as of Jul. 01, 2026, which is 20% above its 10-year median of 0.64. GuruFocus rates ATXI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,229 Biotechnology companies, Avenue Therapeutics ranks better than 88.61% on this metric.
The historical rank and industry rank for Avenue Therapeutics's PB Ratio or its related term are showing as below:
ATXI'
s PB Ratio Range Over the Past 10 Years
Min: 0.26 Med: 0.64 Max: 1.81
Current: 0.77
During the past 11 years, Avenue Therapeutics's highest PB Ratio was 1.81. The lowest was 0.26. And the median was 0.64.
ATXI's PB Ratio is ranked better than 88.61% of 1229
companies
in the Biotechnology industry
Industry Median: 2.87
vs ATXI: 0.77
During the past 12 months, Avenue Therapeutics's average Book Value Per Share Growth Rate was -67.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -78.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -72.70% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Avenue Therapeutics was 50.30% per year. The lowest was -80.60% per year. And the median was -63.65% per year.
Back to Basics: PB Ratio
Avenue Therapeutics (OTCPK:ATXI) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Avenue Therapeutics PB Ratio Related Terms
Avenue Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Avenue Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Avenue Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avenue Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Avenue Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Avenue Therapeutics (ATXI) has a PB Ratio of 0.77 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Avenue Therapeutics and its competitors. This is 20% above median its historical median of 0.64. Over the past decade, Avenue Therapeutics' PB Ratio has ranged from 0.26 to 1.81. According to the industry distribution chart, Avenue Therapeutics ranks #140 out of 1229 companies in the Biotechnology industry, placing it in the top 11.4%.
Is Avenue Therapeutics' PB Ratio too high?
Avenue Therapeutics' current PB Ratio of 0.77 is 20% above median its 10-year median of 0.64. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 1.81. The Biotechnology industry median PB Ratio is 2.87. Avenue Therapeutics' value of 0.77 is 73.2% below this industry median. Based on the distribution chart, Avenue Therapeutics ranks #140 out of 1229 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avenue Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Avenue Therapeutics' PB Ratio compare to AGTX and CLSDQ?
According to the Biotechnology industry distribution chart, Avenue Therapeutics ranks #140 out of 1229 companies for PB Ratio. This places Avenue Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.87. Avenue Therapeutics' value of 0.77 is 73.2% below this benchmark. Historically, Avenue Therapeutics' own PB Ratio has ranged from 0.26 to 1.81 over the past decade. While the company's 10-year median is 0.64 vs. the industry median of 2.87, Avenue Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.87, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avenue Therapeutics's current PB Ratio of 0.77 is 73.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Avenue Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avenue Therapeutics's current PB Ratio is 0.77, which is 20% above median its own 10-year median of 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avenue Therapeutics stock overvalued right now?
Avenue Therapeutics (ATXI) has a current PB Ratio of 0.77. The current PB Ratio is 0.77, which is 20% above median its 10-year median of 0.64 and 73.2% below the Biotechnology industry median of 2.87. Avenue Therapeutics' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Avenue Therapeutics (ATXI), the current PB Ratio is 0.77 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
33GF Score
Get the complete analysis for ATXI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATXI has been successfully added to your 
